Results 61 to 70 of about 1,483,959 (183)
Background: Superficial plaque erosion causes many acute coronary syndromes. However, mechanisms of plaque erosion remain poorly understood, and we lack directed therapeutics for thrombotic complication.
Roberto Molinaro +9 more
semanticscholar +1 more source
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo +3 more
wiley +1 more source
The Association between Prevalence of JAK2V617F Mutation and Blood Indicies in Groups of Patients with Myeloproliferative Neoplasms in Rasul Akram Hospital [PDF]
Introduction: Myeloproliferative neoplasms (MPNs) are a group of clonal malignant hematologic disease, where the main and common members are; polycythemia vera (PV), primary myelofibrosis (PMF), and essential thrombocytosis (ET).
Akram Asghari +6 more
doaj +1 more source
Past studies described interactions between normal megakaryocytes, the platelet precursors, and bone cell precursors in the bone marrow. This relationship has also been studied in context of various mutations associated with increased number of ...
Aikaterini Karagianni +4 more
doaj +1 more source
Mutant NPM1 in Acute Myeloid Leukemia Initiation and Maintenance
NPM1 mutations drive acute myeloid leukemia by acting as neomorphic transcriptional regulators that cooperate with Menin–MLL and XPO1 to sustain HOX/MEIS1 expression and block differentiation. Targeting these mutant‐specific transcriptional dependencies provides a rational therapeutic strategy for NPM1‐mutated AML.
Yanan Jiang +3 more
wiley +1 more source
Polycythemia vera (PV) is a myeloproliferative disorder most commonly associated with JAK2V617F mutation. Cerebral venous sinus thrombosis (CVST) has a wide range of etiologies and PV is one of them. CVST associated with PV has a poor prognosis.
Akanksha Singh +4 more
doaj +1 more source
The Study of Thrombosis in JAK2V617F Mutated Myeloproliferative Neoplasms
Introduction: Thrombosis is the most important risk factor affecting event-free survival and overall survival (OS) of patients with myeloproliferative neoplasms (MPNs). To explore the risk factors of thrombosis in patients with JAK2V617F-mutated MPN, a cohort of 1537 Chinese patients with JAK2V617F-mutated MPN was retrospectively analyzed for clinical ...
Jie Bai +11 more
openaire +1 more source
FREQUENCY OF MPL AND JAK2 EXON12 GENE MUTATION IN MYELOPROLIFERATIVE NEOPLASMS
Objective: Detection of MPL and JAK2 exon12 gene mutation in myeloproliferative neoplasms (MPN) in JAK2V617F negative Myeloproliferative Neoplasms. Study Design: Cross sectional study.
Sana Latif +3 more
doaj +4 more sources
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet +11 more
wiley +1 more source
Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg [PDF]
Venous thromboembolism (VTE) can be the first presenting symptom in myeloproliferative neoplasms (MPN). Studies have demonstrated a high prevalence of the JAK2V617F mutation in patients with splanchnic vein thrombosis. Fewer studies have been done in patients with thrombosis outside the splanchnic area, showing a lower prevalence although the clinical ...
Lauw, Mandy N. +8 more
openaire +2 more sources

